Galeterone

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Galeterone
Galeterone.svg
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ECHA InfoCard 100.233.599
Chemical and physical data
Formula C26H32N2O
Molar mass 388.25
3D model (JSmol)

Galeterone (developmental code names TOK-001, VN/124-1) is a novel steroid antiandrogen that was under development by Tokai Pharmaceuticals for the treatment of prostate cancer.[1] It possesses a unique dual mechanism of action, acting as both an androgen receptor antagonist and a CYP17A1 inhibitor, the latter of which prevents the biosynthesis of androgens.[2] As a CYP17A1 inhibitor, galeterone shows selectivity for 17,20-lyase over 17α-hydroxylase.[3]

Galeterone was being compared to enzalutamide in a phase III clinical trial (ARMOR3-SV) for AR-V7-expressing metastatic castration-resistant prostate cancer.[4][5] Tokai announced the discontinuation of ARMOR3-SV on July 26, 2016, after a data monitoring committee determined that the trial was unlikely to meet its endpoint.[6] On August 22, 2016, the company announced the discontinuation of their phase II expansion (ARMOR2) as well.[7]

In the week following cancellation of the ARMOR3-SV clinical trial, Tokai announced a reduction of its workforce by around 60% to a total of 10 "full-time equivalent employees."[8] On December 22, 2016, a definitive share purchase agreement was announced, under which shareholders of Otic Pharma Ltd. would become the majority owners of Tokai Pharmaceuticals Inc., resulting in a NASDAQ-listed company (OticPharma, Inc.) focused on the development and commercialization of products for ear, nose, and throat disorders.[9]

In August 2017, the development of galeterone was discontinued.[1]

References[edit]

  1. ^ a b http://adisinsight.springer.com/drugs/800031243
  2. ^ Brawer MK (2008). "New treatments for castration-resistant prostate cancer: highlights from the 44th annual meeting of the American Society of Clinical Oncology, May 30–June 3, 2008, Chicago, IL". Rev Urol. 10 (4): 294–6. PMC 2615106Freely accessible. PMID 19145273. 
  3. ^ Yin L, Hu Q (2014). "CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents". Nat Rev Urol. 11 (1): 32–42. doi:10.1038/nrurol.2013.274. PMID 24276076. 
  4. ^ "A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-02-27. 
  5. ^ Silberstein, John L.; Taylor, Maritza N.; Antonarakis, Emmanuel S. (2016-04-01). "Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer". Current Urology Reports. 17 (4): 29. doi:10.1007/s11934-016-0584-4. ISSN 1534-6285. PMC 4888068Freely accessible. PMID 26902623. 
  6. ^ http://www.businesswire.com/news/home/20160726005553/en/Tokai-Pharmaceuticals-Announces-Clinical-Update
  7. ^ http://seekingalpha.com/news/3204773-tokai-pharma-flux-lead-product-candidate-galeterone-enrollment-mid-stage-prostate-cancer
  8. ^ http://www.fiercebiotech.com/biotech/tokai-pharmaceuticals-takes-ax-to-60-workforce-after-phiii-blowout
  9. ^ https://www.streetinsider.com/Corporate+News/Otic+Pharma+to+Become+Majority+Owner+of+Tokai+Pharma+(TKAI)/12366309.html